NEW YORK (GenomeWeb) – Myriad Genetics announced late Friday afternoon that 17 new insurance plans have released positive coverage policies for its EndoPredict breast cancer test.

The plans include Blue Shield of California, Humana, and multiple regional plans. Further, Myriad said, Highmark Blue Cross Blue Shield, Independence Blue Cross, and Health Care Service Corporation have posted positive coverage policies which take effect in July 2017. These plans altogether represent more than 35 million covered lives raising the total of lives covered for EndoPredict to 109 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.